SCHEMBL2194455

SCHEMBL2194455

Cn1c(=[Pt])n(C)c2ccccc21.IN(I)C1CCCCCC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.37
LMNA P02545 3/20 0.37
MEN1 O00255 2/20 0.34
KDM4E B2RXH2 2/20 0.34
ALDH1A1 P00352 1/20 0.34
TSHR P16473 1/20 0.34
HTT P42858 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
GAA P10253 1/20 0.33
PPARG P37231 1/20 0.33
NCOA2 Q15596 1/20 0.33
TP53 P04637 1/20 0.32
XBP1 P17861 1/20 0.32
CRHBP P24387 1/20 0.32
MAPK1 P28482 1/20 0.32
CRHR2 Q13324 1/20 0.32
PER2 O15055 1/20 0.32
CRY1 Q16526 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2193953 1.00 KMT2A (0.37) KMT2ALMNAMEN1KDM4EALDH1A1
SCHEMBL2193811 0.98 LMNA (0.35) KMT2ALMNAMEN1KDM4EALDH1A1
SCHEMBL2197553 0.97 DDB1 (0.33) KMT2ALMNAALDH1A1DDB1CRBN
SCHEMBL2193962 0.92 DDB1 (0.34) KMT2ALMNADDB1CRBN
SCHEMBL2193796 0.84 ATM (0.35) KMT2ALMNAMEN1KDM4EALDH1A1
SCHEMBL2197883 0.84 KMT2A (0.34) KMT2ALMNAMEN1KDM4EALDH1A1
SCHEMBL2194479 0.83 ALDH1A1 (0.38) KMT2ALMNAMEN1KDM4EALDH1A1
SCHEMBL2192492 0.83 ALDH1A1 (0.38) KMT2ALMNAMEN1KDM4EALDH1A1
SCHEMBL2195495 0.81 ALDH1A1 (0.36) KMT2ALMNAMEN1KDM4EALDH1A1
SCHEMBL2194997 0.79 ALDH1A1 (0.34) LMNAKDM4EALDH1A1TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8980875-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2015-03-17 US claimed
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) 2013-12-19 US claimed
US-8481522-B2 Platinum-N-heterocyclic carbene derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-07-09 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US claimed
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2011-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130338128-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 KMT2A 4286/4885LMNA 2301/4885MEN1 766/4885
US-20110172199-A1 PLATINUM-N-HETEROCYCLIC CARBENE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SCO2, C3AR1, IDH1 KMT2A 4286/4885LMNA 2301/4885MEN1 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.